Table 2.
Summary of studies included in the meta-analysis*
| Author [Ref], year | Study design | Centres (n) | Plastic stent | LAMS/BFMS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean age (years) | Male (%) | Etiology: EtOH(%)/ stone(%)/ other(%) | Location of WON (%) | Stent type | Length of FU | Mean age (years) | Male (%) | Etiology: EtOH(%)/ stone(%)/ other(%) | Location of WON | Stent type | Length of FU | |||
| Abu Dayyeh, 2018 | Obs | 1 | 59.7 | 77.8 | 2.8/66.7/ 30.5 | 72.2 pancreatic/ peripancreatic only, 27.8 paracolic involvement | PS (7 and 10 Fr) | At least 12 weeks | 52.7 | 77.6 | 25.9/39.7/ 34.5 | 84.5 pancreatic/ peripancreatic only, 15.5 paracolic involvement | LAMS (Axios 15 mm) (n. 45) 6 cm, 18 or 20 mm diameter fully covered metal stent, Niti-S; Taewoong Medical, Gyeonggi-do, South Korea) (n: 12) | At least 12 weeks |
| Bang, 2019 | RCT | 1 | 60.3 | 55.2 | 17.2/34.5/ 48.3 | 20.7 H, 79.3 B/T | PS (7 Fr) | 24 weeks | 55.8 | 64.5 | 29.0/19.4/ 51.6 | 29.0 H, 71.0 B/T | LAMS (cautery- enhanced Axios, 15 mm) | 24 weeks |
| Bapaye, 2017 | Obs | 1 | 40.7 | 88.5 | 60.7/ 27.9/ 11.5 | 9.8 H, 86.9 B/T, 3.3 perihepatic | PS (7 Fr) | 6–8 weeks | 43.9 | 86.1 | 56.9/15.3/ 27.8 | 11.1 H/ 86.1 B/T, 2.8 perihepatic | BFMS (Nagi stent) | 6–8 weeks |
| Chen, 2019 | Obs | 14 | 57.0 | 52.9 | 17.2/41.4/ 41.4 | 14.9 H, 66.7 B, 16.1 T | PS (size NA) | 62.3 weeks | 54.0 | 47.1 | 26.7/42.6/ 30.7 | 18.6 H, 66.7, 7.8 T | LAMS (Axios) | 20.6 weeks |
| Faisal, 2018† | Obs | 4 | — | — | — | — | PS (size NA) | 54 weeks | — | — | — | — | LAMS (type NA) | 54 weeks |
| Ge, 2018† | Obs | 1 | — | — | — | — | PS (size NA) | At least 19.5 weeks | — | — | — | — | LAMS (type NA) | At least 11 weeks |
| Mukai, 2015 | Obs | 1 | 55.9 | 77.8 | 63.0/3.7/ 33.3 | 40.7 H, 33.3 B, 25.9 T | PS (7Fr) | NA | 54.4 | 86.0 | 62.8/11.6/ 25.6 | 16.3 H, 46.5 B, 37.2 T | LAMS/BFMS (10- and 15- mm Axios; 16-mm Niti-S, and 12-mm Hanaro) | NA |
| Sahar, 2017 | Obs | 1 | 53.2 | 56.0 | 20.0/48.0/ 32.0 | — | PS (7Fr, 3 cm) | ~34 weeks | 51.2 | 68.0 | 16.0/52.0/ 32.0 | — | LAMS (Axios, 10 mm [56%] and 15 mm [44%]) | ~28 weeks |
| Siddiqui, 2017 | Obs | 2 | 56.3 | 64.2 | 34.0/34.0/ 32.0 | 17.9 H, 82.1 B/T | PS (10 Fr) | 24 weeks | 51.5 | 89.3 | 32.6/46.5/ 20.9 | 4.7 H, 95.3 B/T | LAMS (10 and 15 mm Axios)‡ | 24 weeks |
B, body; BFMS, biflanged metal stents; EtOH, alcohol; Fr, French; FU, follow-up; H, head; LAMS, lumen-apposing metal stents; NA, not available; Obs, observational; PS, plastic stents; RCT, randomized controlled trial; T, tail.
†Baseline characteristics for plastic stents and LAMS/BFMS groups.
‡This study had a third group treated with self-expandable metal stents, but the data from this group were not extracted for this meta-analysis.